Tohoku University

Sanbio, Inc.

Clio, Inc.

Other

Nagoya University

Gifu University

Life Science Institute, Inc.

The University of Tokyo

Kyoto University

The University of Toyama

Kyoto Prefectural Public University Corporation

National Cerebral and Cardiovascular Center

National University Corporation Tokai National Higher Education and Research System

Dezawa, Mari

Kitada, Masaaki

Mari Dezawa

Masanori Yoshida

Masahiko Takano

Hajime Sawada

Hiroshi Kanno

Yoshinori Fujiyoshi

Youichi Nabeshima

Shinya Minatoguchi

Shinobu Shimizu

Yoshiaki Sato

Toshihiro Yamamoto

Akira Furuta

Kotaro Yoshimura

Teiji Tominaga

Toshihiko Suzuki

Hiroto Hara

Masaaki Mizuno

Tokunori Yamamoto

Yo-ichi Nabeshima

Keita Mori

Michiaki Unno

Masahiro Hayakawa

Yasumasa Kuroda

Katsuhiro Hosoyama

Mikio Hoshino

Satoaki Matoba

Yoshikatsu Saiki

Kahori Kinoshita

Shohei Wakao

Satoshi Kuroda

Yasuhiro Shindo

Masahiro Tsuji

Hiroshi Yabuki

Yoshinori Okada

Naoya Masutomi

Yuma Kitase

The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

Therapy for interstitial cystitis by pluripotent stem cells

The purpose of the present invention is to provide a novel medical use of pluripotent stem cells (Muse cells) in the regenerative medicine area. Provided are a cell preparation and a medicinal composition for ameliorating and treating chronic lung disease in newborns, said cell preparation and medicinal composition comprising SSEA-3-positive pluripotent stem cells isolated from a mesenchymal tissue in a living body or cultured mesenchymal cells. The cell preparation according to the present invention is based on a mechanism whereby the aforesaid disease is ameliorated and treated by administering Muse cells to a subject suffering from the disease and engrafting the cells in lung tissues.

Amelioration and treatment of chronic lung disease using pluripotent stem cells

The purpose of the present invention is to provide a cell creation method that enables a reduction in cost and time, that is highly safe, and that has great potential for being industrially applied. Provided by the present invention is a method for inducing differentiation of pluripotent cells in vitro into cells having a same phenotype and function as information-presentation cells, the method comprising co-culturing pluripotent cells or a cellular fraction having said pluripotent cells concentrated therein, together with damaged cells or dead cells derived from information-presentation cells, or together with a portion of the damaged cells or dead cells derived from information-presentation cells.

Method for inducing differentiation of pluripotent stem cells in vitro

There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.

Neural precursor cells expressing exogenous Notch intracellular domain

A cell product for prevention and/or treatment of vascular disorders such as aortic aneurysm, comprising a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell (Muse cell).

Method of treating aortic aneurysm using muse cells

Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.

Pluripotent stem cell that can be isolated from body tissue

The purpose of the present invention is to provide a novel medicinal use in regeneration medicine, said medicinal use comprising using pluripotent stem cells (Muse cells). Provided is a cell preparation for treating skin ulcer, said cell preparation comprising SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue of a living organism or cultured mesenchymal cells. The cell preparation according to the present invention is based on such mechanism of skin tissue regeneration that, when the Muse cells are administered to a skin ulcer site of a subject suffering from the aforesaid disease, the Muse cells differentiate into skin-constituting cells.

Pluripotent stem cell for treating diabetic skin ulcer

An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.

Pluripotent stem cell for treatment of cerebral infarction

Provided is a test method comprising a step for measuring the number of SSEA-3-positive pluripotent stem cells present in a blood sample collected from a subject, the test method providing a prognosis for cerebral infarction in the subject, and the diagnosis or prediction of asymptomatic cerebral infarction or the risk of cerebral infarction after a transient ischemic attack in the subject using the number of pluripotent stem cells as an index.

Mobilization of pluripotent stem cells for ischemic cerebral infarction

An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.

Pluripotent stem cell that induces repair and regeneration after myocardial infarction

The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.

Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to damage

An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease.

Multilineage-differentiating stress enduring (MUSE) cells for treatment of chronic kidney disease

Treatment of CNS disorders using descendants of MSCS expressing an exogenous Notch intracellular domain

Growing community of inventors

Miyagi, Japan

Mari Dezawa